NICE estimates there are 115,000 new diagnoses of COPD and 80,000 (average) asthma diagnoses per year.¹

The annual economic burden of asthma and COPD on the NHS in the UK is estimated at £3 billion and £1.9 billion respectively.¹

Appropriate medicines use, particularly inhalers, is evidenced to reduce exacerbations and mortality. With optimal therapy, 90% of people with asthma could be well controlled.¹

Fluticasone and Salmeterol inhaler combinations alone cost the NHS around £970,000,000 per year with an average cost to the NHS of £36.37 per patient, per month.²

Evidence that widespread implementation of inhaled corticosteroids decreases unscheduled healthcare utilisation.¹

Inhaler prescribing is part of routine care as recommended by NICE. This applies to annual reviews where there is an opportunity to improve quality.¹